BridgeBio Pharma

Research only

BBIO · Tracked drugs and regulatory events

Tracked programs

1 program

autosomal dominant hypocalcemia type 1 (ADH1)

Publication and retrieval dates are shown separately. Market rules determine which evidence can resolve an outcome.

sponsor-releaseinvestor.bridgebio.com

Sponsor update lists encaleret for ADH1 under Priority Review with a May 8, 2027 FDA target.

sponsor-releaseinvestor.bridgebio.com

Sponsor describes encaleret as an orally administered small molecule targeting the calcium-sensing receptor.

Registry identifies the associated compound, condition and sponsor; trial completion is separate from FDA action.